中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
16期
4-6
,共3页
哮喘%吸烟%糖皮质激素%白三烯受体拮抗剂
哮喘%吸煙%糖皮質激素%白三烯受體拮抗劑
효천%흡연%당피질격소%백삼희수체길항제
Asthma%Smoking%Corticosteroid%Leukotriene receptor antagonist
目的：探讨白三烯受体拮抗剂对吸烟哮喘患者病情控制的影响。方法：选取2013年3-12月在门诊就诊的110例吸烟哮喘患者，按照随机数字表法将其分为对照组54例和观察组56例。对照组给予吸入糖皮质激素（布地奈德）治疗，必要时吸入β2受体激动剂；观察组在此治疗基础上加用孟鲁司特钠治疗，疗程4周。观察比较两组治疗前后哮喘控制测试（ACT）评分、哮喘症状评分、晨间及夜间呼气峰流速（PEF）。结果：观察组治疗后ACT评分、晨间及夜间PEF%pred均明显高于治疗前及对照组，且哮喘症状评分明显低于治疗前及对照组，差异均有统计学意义（P<0.05）。对照组治疗前后各项指标比较差异均无统计学意义（P>0.05）。结论：白三烯受体拮抗剂能够使吸烟哮喘患者的病情控制得到改善，可能是治疗吸烟哮喘患者的一种有效药物。
目的：探討白三烯受體拮抗劑對吸煙哮喘患者病情控製的影響。方法：選取2013年3-12月在門診就診的110例吸煙哮喘患者，按照隨機數字錶法將其分為對照組54例和觀察組56例。對照組給予吸入糖皮質激素（佈地奈德）治療，必要時吸入β2受體激動劑；觀察組在此治療基礎上加用孟魯司特鈉治療，療程4週。觀察比較兩組治療前後哮喘控製測試（ACT）評分、哮喘癥狀評分、晨間及夜間呼氣峰流速（PEF）。結果：觀察組治療後ACT評分、晨間及夜間PEF%pred均明顯高于治療前及對照組，且哮喘癥狀評分明顯低于治療前及對照組，差異均有統計學意義（P<0.05）。對照組治療前後各項指標比較差異均無統計學意義（P>0.05）。結論：白三烯受體拮抗劑能夠使吸煙哮喘患者的病情控製得到改善，可能是治療吸煙哮喘患者的一種有效藥物。
목적：탐토백삼희수체길항제대흡연효천환자병정공제적영향。방법：선취2013년3-12월재문진취진적110례흡연효천환자，안조수궤수자표법장기분위대조조54례화관찰조56례。대조조급여흡입당피질격소（포지내덕）치료，필요시흡입β2수체격동제；관찰조재차치료기출상가용맹로사특납치료，료정4주。관찰비교량조치료전후효천공제측시（ACT）평분、효천증상평분、신간급야간호기봉류속（PEF）。결과：관찰조치료후ACT평분、신간급야간PEF%pred균명현고우치료전급대조조，차효천증상평분명현저우치료전급대조조，차이균유통계학의의（P<0.05）。대조조치료전후각항지표비교차이균무통계학의의（P>0.05）。결론：백삼희수체길항제능구사흡연효천환자적병정공제득도개선，가능시치료흡연효천환자적일충유효약물。
Objective:To investigate the impact of leukotriene receptor antagonist on the disease control of smoking asthmatic patients.Method:110 smoking asthmatic patients in the outpatient clinic from March 2013 to December 2013 were selected.They were randomly divided into the control group for 54 cases and the treatment group for 56 cases according to the random number table method.The control group was treated with inhaled corticosteroid(budesonide), and inhaledβ2 agonist when necessary.The treatment group was treated with montelukast sodium for 4 weeks on the basis of the control group.Asthma Control Test(ACT)score,asthma-symptom score and morning and night PEF were compared between the two groups before and after treatment.Result:The ACT score,morning and night PEF%pred of the treatment group after treatment were significantly higher than before treatment and the control group,asthma-symptom score after treatment was significantly lower than before treatment and the control group,the differences were statistically significant (P<0.05).In the control group,the indicators before and after treatment comparison difference had no statistical significance(P>0.05).Conclusion:Leukotriene receptor antagonist can improve the control of disease,may be an effective drug in the treatment of smoking asthmatic patients.
